We have recently shown that human monocytes and U937 cells possess two molecular classes of Fcy receptor. One, a 72,000-mol-wt sialoglycoprotein, has high affinity for certain subclasses of human and murine monomeric IgG. The other is a 40,000-mol-wt protein (p40) with low affinity for monomeric IgG but with the capacity to bind IgG aggregates or IgG-coated particles.
Introduction
The existence of Fc'y receptors on human platelets has been supported by several lines of evidence, including Fc-dependent secretory and aggregation responses to IgG aggregates and IgGbearing immune complexes (1) (2) (3) (4) (5) (6) , direct radioligand binding studies with IgG dimers and larger oligomers (7) , and a report of a KBr-solubilized 255,000-mol-wt platelet membrane glycoprotein exhibiting reactivity with aggregated IgG (8) .
In recent reports from this laboratory (9, 10) evidence was presented that human monocytes and a related cell line, U937, possess two molecular classes of Fcy receptors: one, the high affinity 72,000-mol-wt sialoglycoprotein receptor (p72)' previously described ( 11) ; the other, a newly recognized 40,000-molwt membrane protein (p40). Molecular and functional analysis ofthe p40 protein was facilitated by the development ofa murine anti-p40 monoclonal antibody (MAb). This MAb also recognizes p40 molecules on human granulocytes, on the erythroblastic cell line, K562, and, more weakly, on the B lymphocyte line, Daudi (9) .
In the present study on human platelets, application of this ( 14) .
After preliminary studies to establish correct conditions, papain digests of IgG2b anti-p40 (IV. Rosenfeld, and J. P. Leddy, unpublished observations). taining 2 mM CaC12 and 2% BSA. The platelets were counted electronically, adjusted to 300,000/mm3 in the same buffer, and held at room temperature (RT) until tested. For platelets involved in Fcy receptor solubilization, the purity of the platelet preparation was assessed. Electronic counting ofwashed platelets (4.47 X 105/mm3) revealed leukocyte contamination of -600/mm3 (0.134% of the platelet count) and erythrocyte contamination at 1 X 104/mm3. Microscopic examination of Wright's stained cytocentrifuge smears demonstrated that the great majority of contaminating leukocytes were lymphocytes, e.g., in the preparation used in Fig. 1 , there were 73% lymphocytes, 25% monocytes, and 2% neutrophils. Independent analysis by flow microfluorimetry has revealed no demonstrable binding of anti-p40 to normal peripheral blood lymphocytes (Looney, R. J., D. H. Ryan, and C. L. Anderson, unpublished observations). U937 cells were grown and prepared for radiolabeling as previously described (19) .
Surface-radioiodination ofplatelets and U937 cells. Washed platelets (2 X 109) in 0.7 ml Tyrode's buffer containing 6.6 mM EDTA were added to a flat-bottomed glass vial precoated with 5 gg chloroglycouril (Pierce Chemical Co., Rockford, IL) followed by 1 mCi carrier-free Na'211 (Amersham Corp., Arlington Heights, IL). After a 30-min incubation at room temperature, the reaction was quenched by addition of 5 mM KI in Tyrode's/EDTA. The platelets were immediately transferred to a clean tube, washed twice in the same buffer, transferred to a second tube, and washed one more time in Tyrode's/EDTA/KI. U937 cells (1 X 107) were radiolabeled in similar fashion (11, 19) .
Pelleted labeled platelets or U937 cells were solubilized in 2.0 ml or 0.2 ml, respectively, of a pH 7.1-buffer mixture containing 1% NP-40, 20 mM Tris, 110 mM NaCl, 10 mM EDTA, 5 mM KI, 10 lg/ml pepstatin, 10 Ag/ml chymostatin, 10 Ag/ml leupeptin, 10 Ag/ml antipain, and 1 mM phenylmethyl sulfonylfluoride (all inhibitors from Sigma Chemical Co.). After a 30-min incubation on ice, the lysates were subjected to centrifugation at 12,000 g for 20 min at 4°C. Supernatants were recovered and held on ice. The percentage of radioactivity precipitable by 12.5% TCA was determined: platelets, 25-42% (seven experiments); U937 cells, 4.8-5.4% (two experiments).
Receptor isolation using monoclonal anti-p40. 100 Al lysate was incubated (1 h on ice) with 50 tl undiluted anti-p40 (IV.3) in culture supernatant (see above) or with control murine antibodies or immunoglobulins. The mixtures were transferred to 1.5-ml microcentrifuge tubes containing 25 Al packed Sepharose-goat F(ab')2 anti-murine Ig that had been washed twice with 1 ml 1% NP-40/5 mM KI in PBS. After incubation for I h on ice with mixing at 10-min intervals, the Sepharose was washed five times in PBS containing 0.5% NP-40, 0.1% SDS, 5 mM KI, and 0.02% NaN3. The contents were transferred to fresh tubes and washed one more time in the same buffer mixture. The Sepharose pellets were suspended in 80 gl Laemmli's (16) sample buffer containing 2% SDS with or without 20 mM dithiothreitol (DTT) (Pierce Chemical Co.), in place of 2-mercaptoethanol, followed by mixing and boiling for 2 min. Addition of 5 Al I M iodoacetamide (Sigma Chemical Co.) was followed by microcentrifugation (Beckman Instruments Inc., Spinco Div., Palo Alto, CA) for 30 s. The supernatants were removed and applied to a 5-15% polyacrylamide gradient slab gel in 0.1% SDS. The gels were stained with Coomassie Blue, dried on filter paper, and then analyzed by autoradiography using XAR-2 film (Eastman Kodak Co., Rochester, NY). Unlabeled high and low molecular weight markers (Bio-Rad Laboratories, Richmond, CA) included myosin (200,000), ,j-galactosidase (130,000), phosphorylase B (94,000), BSA (68,000), ovalbumin (43,000), carbonic anhydrase (30,000), soybean trypsin inhibitor (21,000), and lysozyme (14,300). Radiolabeled BSA was included for alignment ofthe autoradiographs.
Receptor isolation using Sepharose-IgG. Sepharose-IgG and other (control) Sepharose conjugates were washed sequentially with PBS containing 1 Anti-p40 itself did not induce platelet aggregation, at least over the dose range employed. Bridging experiments with a second antibody were carried out by a modification of the above procedure. After 10 Ad diluted anti-p4O (IV.3) had been incubated (RT, 10 min) with 450 A1 washed platelets, 50 gI F(ab')2 goat anti-mouse Ig (60 gg/ml) were added at 37°C, and the mixture was observed for platelet aggregation in parallel with appropriate control mixtures (see below). In such experiments positive results were followed by repeat application of the same antibody concentrations in the presence of apyrase (64 jsg/ml) in order to distinguish ADP-dependent platelet aggregation from agglutination of platelets.
Results
Detergent-solubilized platelets were sequentially exposed to the murine IgG2b MAb anti-p4O (IV.3) and solid phase F(ab')2 goat anti-mouse Ig, and the complexes were eluted by 2% SDS in the presence or absence of 20 mM DTT. Analysis of the eluates by autoradiography of SDS-PAGE slab gels consistently revealed a protein ofMr 40,000 in similar position to that ofp40 extracted from concurrently studied U937 cells (Fig. 1, left, lanes C, and   D , and G, and H). Neither platelet p4O nor U937-p4O appeared to be derived from a higher molecular weight multichain protein since reduction had only a slight effect on apparent molecular weight. Other bands faintly visible in the specific anti-p4O track are also seen in the tracks of eluates derived by exposure to control murine IgG2b (MOPC-141) prior to the solid phase goat F(ab')2 anti-murine Ig (Fig. 1, left, lanes A, and B , and E, and F). The p4O band, however, was not recovered when either (Fig. 1) or IgG2b murine MAb anti-Vkiiib (not shown) was used in place of anti-p4O (IV.3).
The platelet preparation used for this experiment contained a small number of monocytes (0.034% of the platelet count).
Since monocytes contain about the same amount of anti-p40 as do U937 cells, (Looney, R. J., and C. L. Anderson, unpublished observations) the contaminating monocytes could contribute to lanes C and D (Fig. 1, left) no more than 0.7% of the p40 seen in lanes G and H (Fig. 1, left platelets (Fig. 1, right, lane A) . The additional bands, mostly of higher molecular weight, seen in the autoradiograph were also found in eluates derived from the nonspecific adsorbents, Sepharose-myoglobin (Fig. 1, right, completely block platelet aggregation down to a final concentration of 43 ng/ml and reproducibly induced partial inhibition at 17 ng/ml. MOPC-141 produced little or no inhibition at concentrations up to 2,000-fold higher (43 gg/ml). In the same experiments platelet aggregation by ADP plus fibrinogen, by thrombin or by collagen, was unaffected by intact anti-p40 at several concentrations that totally inhibited the responses to aggregated IgG (not shown). Anti-p40 Fab fragments also effectively inhibited platelet responses to aggregated IgG although the protein concentrations required were 10-12-fold higher than for intact anti-p40 (Table  I) (10 ,l) to washed platelets (450 ,ul) in the aggregometer induced a rapid increase in light transmission. Since this was only slightly affected by prior addition of apyrase, this reaction may represent agglutination rather than aggregation. In any event, a 1/4 dilution of UR-1 (tested in the same reaction volumes) produced no observable direct effect on platelets but was assumed to bind at a subagglutinating level. Subsequent addition of aggregated human IgG, however, produced prompt aggregation that was fully comparable with that of control platelets (not shown).
Mab anti-p40 did not directly induce platelet aggregation, at least in the concentrations employed. When washed platelets that had been pretreated (10 min, RT) with anti-p40 (43 ng/ml final concentration) were exposed to a second bridging antibody, i.e., goat F(ab')2 anti-murine IgG, prompt apyrase-sensitive aggregation was observed (Fig. 3) . Appropriate controls using MOPC-141 or UR-l as the first "antibody" prior to the F(ab')2 goat antibody, or addition of the F(ab')2 goat antibody alone, yielded no observable aggregation. We have found that the minimum concentration of intact anti-p40 mediating full inhibition of platelet aggregation by aggregated IgG is very similar to the minimum concentration permitting platelet aggregation by receptor bridging via goat F(ab')2 antibody. The fact that apyrase inhibited this reaction indicates that ADP was required. Therefore the platelet aggregation was an active process, requiring platelet secretion, as opposed to the passive, apyrase-insensitive agglutination produced by UR-1 (see above).
Discussion
Human platelets have been shown to possess a previously undescribed 40,000-mol-wt membrane protein for which the following evidence is consistent with its function as an Fcy receptor. (9, 10) and mouse (21, 22) . On the other hand, our anti-p40 MAb did totally block platelet responses to aggregated IgG. It is conceivable that p40 is the ligand recognition unit of a larger multiprotein complex that can maintain its multicomponent structure in the less stringent conditions of Cheng and Hawiger (8) . This idea has precedent in the proposed multisubunit structure ofthe high affinity IgE receptors of rat mast cells and basophils (23, 24) .
As a candidate for the platelet Fc-y receptor (or at least its ligand-binding unit), the currently known properties of p40 would be consistent with other observations. As an IgG-binding membrane protein in normal human monocytes (9, 10) and, more recently, in granulocytes (Looney, R. J., and C. L. Anderson, unpublished observations), p40 functions essentially as an IgG aggregate receptor, with very low affinity for monomeric IgG. Karas Fc-y receptors possessing high affinity (Ka = 10'-109 M-') for monomeric IgG (1 1, 20) .
Cellular activation by anti-receptor antibody has previously been observed in several systems (26) (27) (28) (29) (30) . In these examples a single application of a polyclonal or monoclonal antibody was effective, whereas in our studies (Fig. 3 ) a second goat F(ab')2 anti-murine Ig antibody was employed. Although we did not test high concentrations of monoclonal anti-p40 (IV.3) alone, because of limited supply, the concentrations tested were equal to those effecting total inhibition of platelet responses to aggregated IgG. We consider it more likely that the need for a second bridging antibody is related to questions of epitope density or accessibility on neighboring p40 molecules, or to the overall density of p40 proteins in platelet membranes.
It will be of interest in future studies with the anti-p40 MAb (or its Fab fragments) (a) to compare the (maximum) number of surface-expressed p40 molecules per platelet with the Fc'y receptor estimates obtained by dimeric IgG binding (7), (b) to probe in greater detail the mechanism of platelet aggregation by Fc'y receptor bridging, and (c) to explore the relationship, ifany, of p40 to extensively studied major glycoproteins of the platelet membrane such as GP Ib (31, 32 
